BR112021024897A2 - Métodos de produção de um anticorpo anti-a4ss7 - Google Patents

Métodos de produção de um anticorpo anti-a4ss7

Info

Publication number
BR112021024897A2
BR112021024897A2 BR112021024897A BR112021024897A BR112021024897A2 BR 112021024897 A2 BR112021024897 A2 BR 112021024897A2 BR 112021024897 A BR112021024897 A BR 112021024897A BR 112021024897 A BR112021024897 A BR 112021024897A BR 112021024897 A2 BR112021024897 A2 BR 112021024897A2
Authority
BR
Brazil
Prior art keywords
antibody
methods
producing
a4ss7
vedolizumab
Prior art date
Application number
BR112021024897A
Other languages
English (en)
Portuguese (pt)
Inventor
Amitava Kundu
Amy Miller
Debra Ameli
George Parks
E Dolan Michael
Nicole Hilo
Olga Paley
Paras Bhatia
R Carter Susan
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112021024897A2 publication Critical patent/BR112021024897A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021024897A 2019-06-10 2020-06-10 Métodos de produção de um anticorpo anti-a4ss7 BR112021024897A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
PCT/US2020/037059 WO2020252069A1 (en) 2019-06-10 2020-06-10 METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
BR112021024897A2 true BR112021024897A2 (pt) 2022-01-18

Family

ID=73781728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024897A BR112021024897A2 (pt) 2019-06-10 2020-06-10 Métodos de produção de um anticorpo anti-a4ss7

Country Status (14)

Country Link
US (1) US20220267449A1 (https=)
EP (1) EP3980466A4 (https=)
JP (2) JP7624414B2 (https=)
CN (3) CN114375307B (https=)
AR (1) AR119270A1 (https=)
AU (1) AU2020290943A1 (https=)
BR (1) BR112021024897A2 (https=)
CA (1) CA3143167A1 (https=)
IL (1) IL288825A (https=)
MA (1) MA56129A (https=)
MX (1) MX2021015300A (https=)
PL (1) PL439809A1 (https=)
TW (1) TW202112818A (https=)
WO (1) WO2020252069A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433947B2 (en) 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2023007516A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Method to control high molecular weight aggregates in an antibody composition
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
CN114375307B (zh) 2025-12-05
PL439809A1 (pl) 2022-12-05
CN121736106A (zh) 2026-03-27
TW202112818A (zh) 2021-04-01
EP3980466A4 (en) 2023-06-07
WO2020252069A1 (en) 2020-12-17
JP7624414B2 (ja) 2025-01-30
CA3143167A1 (en) 2020-12-17
CN119859188A (zh) 2025-04-22
US20220267449A1 (en) 2022-08-25
EP3980466A1 (en) 2022-04-13
JP2025063035A (ja) 2025-04-15
MX2021015300A (es) 2022-02-03
AU2020290943A1 (en) 2022-02-03
JP2022536486A (ja) 2022-08-17
CN114375307A (zh) 2022-04-19
AR119270A1 (es) 2021-12-09
MA56129A (fr) 2022-04-13
IL288825A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112021024897A2 (pt) Métodos de produção de um anticorpo anti-a4ss7
RU2768003C2 (ru) Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
CO6640239A2 (es) Proceso par preparar una composición de inmunoglobulina
FI20155541A7 (fi) Menetelmä ja systeemi polttoainekomponenttien valmistamiseksi
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112021024848A2 (pt) Métodos de purificação de anticorpos e composições dos mesmos
MX2017014278A (es) Sistema modular y proceso para la produccion continua reducida respecto del contenido de microbios y/o procesamiento de un producto.
MX2019008914A (es) Purificacion de iduronato-2-sulfatasa.
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
EP2155221A4 (en) METHOD FOR MODIFYING POLYPHENOL-CONTAINING PLANT MATERIALS AND MEDICAL USES OF MODIFIED POLYPHENOL-CONTAINING PLANT MATERIALS
Bürger et al. Pigment epithelium-derived factor (PEDF) receptors are involved in survival of retinal neurons
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
BRPI1012321A8 (pt) Anticorpos anti-vegf e seus usos
BR112015012854A2 (pt) método para purificar proteínas terapêuticas
EA201491564A1 (ru) Осаждение фракции i-iv-1 иммуноглобулинов из плазмы
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
AR091155A1 (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion
Schiera et al. Extracellular vesicles shed by melanoma cells contain a modified form of H1. 0 linker histone and H1. 0 mRNA-binding proteins
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
Bruzelius et al. Reprogramming human adult fibroblasts into GABAergic interneurons
EA201000769A1 (ru) Катенированные молекулы и содержащие их композиции для иммуностимуляции
Hwang et al. Intracellular Ca2+-mediated AE2 is involved in the vectorial movement of HaCaT keratinocyte
EA201500185A1 (ru) Композиция, содержащая нуклеиновые кислоты паразитических, патогенных или инвазивных биологических систем для ингибирования и/или контроля роста указанных систем, и способ ее получения
Bassett et al. Differential expression of microRNA (miR-27, miR-145) among dental pulp stem cells (DPSCs) following neurogenic differentiation stimuli
Salamanna et al. Gender-specific differences in human vertebral bone marrow clot